The two medications being compared are romosozumab and denosumab. Participants will receive one of these treatments through a subcutaneous injection, which means the medicine is delivered into the fatty layer of tissue just under the skin. One group will receive romosozumab, while the other group will receive denosumab for comparison.

During the study, the condition of the heart arteries will be monitored. This is done using a computed tomography scan, a type of imaging that uses X-rays to create detailed pictures of the inside of the body. The researchers will look at changes in the heart’s arterial health over a period of 12 months of therapy to see how the two medications compare.

The study will test whether taking everolimus tablets, performing resistance training (strength-building exercises), or using both approaches together can help improve bone health. Some participants will receive placebo tablets instead of the active medication. The treatment and exercise program will continue for 24 weeks.

During the study, researchers will monitor changes in bone health using various measurements, including markers of bone turnover in the blood and bone density scans. They will also assess muscle strength and overall health status. The study aims to find new ways to support bone health in postmenopausal women through the combination of medication and exercise.

The purpose of the study is to determine if these treatments can enhance bone formation over a period of 24 weeks. Participants will be divided into groups to receive either Everolimus, engage in physical training, or both. The study will monitor changes in bone health by measuring specific markers in the blood that indicate bone formation and turnover. Additionally, bone density will be assessed using a special type of X-ray called DXA, and bone structure will be examined using a detailed imaging technique known as HR-pQCT.

Throughout the study, other health aspects such as muscle function, balance, heart and lung health, and metabolic health will also be evaluated. This includes checking weight, body composition, and blood sugar levels. The study will last for 24 weeks, with assessments conducted at the beginning, during, and at the end of the study period to track any changes in these health indicators.

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of AGA2118 in increasing bone mineral density (BMD) in postmenopausal women with low bone mass. The study will last for about 12 months, during which participants will receive regular injections and have their bone density measured at different times. The main focus is on the change in BMD at the lumbar spine, which is the lower part of the back, after 12 months of treatment. Additionally, changes in BMD at other sites like the hip and forearm will also be monitored.

Participants will be monitored for any new bone fractures and other health changes throughout the study. The trial aims to find the most effective dose of AGA2118 and to ensure it is safe for use in treating postmenopausal osteoporosis. This research could lead to new treatment options for women with this condition, helping to improve their bone health and reduce the risk of fractures.

The purpose of the study is to compare two different ways of using zoledronic acid after stopping denosumab. One method is based on specific biological markers in the body, while the other follows a standard treatment plan. The study will last for one year, during which participants will receive the treatment and have their bone health monitored. Some participants may receive a placebo instead of the active treatment.

Throughout the study, the health of the participants’ bones will be checked using a special type of X-ray called dual-energy X-ray absorptiometry (DXA). This will help determine if the treatment is effective in maintaining bone density and preventing fractures. The study will also look at changes in certain markers in the blood that are related to bone health. Participants will be monitored for any side effects or adverse events during the study period.

The study will compare denosumab with placebo to determine its effectiveness. Participants will receive either 60 mg of denosumab or saline solution (salt water) injections. The purpose of this research is to evaluate how denosumab influences muscle mass, strength, and how well the body processes insulin in postmenopausal women who have both diabetes and bone health concerns.

The treatment period will last for 12 months, during which various measurements will be taken to track changes in muscle strength and the body’s response to insulin. Throughout the study, participants will undergo regular check-ups to monitor their progress and any changes in their condition. The study will measure several factors related to bone health, muscle function, and blood sugar control to better understand how the medication works.

Participants in the study will receive either BP16 or EU-Prolia through a method called subcutaneous injection, which means the medication is given under the skin. The study will also include a group that receives a placebo. The trial will last for about a year, during which participants will have regular check-ups to monitor their bone health and overall well-being. The study will look at changes in bone mineral density, which is a measure of bone strength, and other markers of bone health.

In addition to BP16 and EU-Prolia, the study will also involve the use of Vitamin D3 and calcium carbonate, which are commonly used to support bone health. Participants will be monitored for any side effects or reactions to the medications. The study aims to provide valuable information on the effectiveness and safety of BP16 for women with post-menopausal osteoporosis, potentially offering a new treatment option for this condition.